Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04478266
Title SAR439859 Plus Palbociclib as First Line Therapy for Patients With ER(+) HER2(-) Advanced Breast Cancer (AMEERA-5)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Sanofi
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole + Palbociclib

Amcenestrant + Goserelin + Palbociclib

Goserelin + Letrozole + Palbociclib

Amcenestrant + Palbociclib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.